Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financi...(r Altropane molecular imaging agent. Th...),Health

for enrollment of up to 80 subjects to generate an image training set.

These images will be used to train the expert readers in the study, as

is customary for clinical trials of molecular imaging agents.

- We are pursuing development and commercialization partnerships for our

molecular imaging, nerve repair and regenerative therapy assets. We

expect to continue confidential discussions with franchise leaders

interested in our molecular imaging and regenerative therapeutic

pipelines. We expect discussions to advance materially toward

partnerships over the course of this year.

Conference Call Access Information

The company will host a conference call to discuss results on, May 15, 2008, at 9:00 a.m. Eastern Daylight Time. To access the conference call, please dial 877-795-3649 for domestic and 719-325-4817 international. The code for this conference call is 1073493. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, http://www.alseres.com, within 48 hours following the conference call and will be available through Thursday, May 29th, 2008.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inos
'/>"/>